AnGes, Inc. (AMGXF)
0.3602
0.00 (0.00%)
USD |
OTCM |
Dec 05, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 139.06M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 21.61 |
| Price to Book Value | 4.921 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0408 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.36% |
Profile
| AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan. |
| URL | https://www.anges.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | Osaka |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 10, 2026 |
| Last Earnings Release | Nov. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan. |
| URL | https://www.anges.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | Osaka |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 10, 2026 |
| Last Earnings Release | Nov. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |